Os therapies requests meeting with fda to gain agreement on surrogate endpoint(s) for breakthrough therapy designation & accelerated approval of ost-her2 in the prevention of recurrence of fully resected, lung metastatic osteosarcoma

New york--(business wire)--os therapies (nyse-a: ostx) (“os therapies” or “the company”), a clinical-stage immunotherapy and antibody drug conjugate (adc) biopharmaceutical company, today announced that it has submitted a request for a formal meeting with the center for biologics evaluation and research (cber) of the united states food & drug administration (fda) to gain alignment on the clinical endpoints required to support breakthrough therapy designation (btd) and accelerated approval v.
OST Ratings Summary
OST Quant Ranking